- Exchange: Frankfurt
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
AVANIR Pharmaceuticals Inc+ Add to Watchlist
AV2B:GR2.146 EUR 0.624 22.53%
As of 02:08:51 ET on 12/12/2013.
Company Profile for AVANIR Pharmaceuticals Inc (AV2B)
AVANIR Pharmaceuticals Inc. develops, acquires, and markets treatments for central nervous system disorders, inflammation, and infectious diseases. The Company develops treatments for pseudobulbar affect, diabetic peripheral neuropathic pain, and other conditions. AVANIR out-licensed its moniclonal antibodies, and produces an over-the-counter treatment for cold sores.
AVANIR Pharmaceuticals Inc
Key Executives for AVANIR Pharmaceuticals Inc (AV2B)
|Keith A KatkinPresident/CEO||Rohan PalekarSenior VP/Chief Commercial Ofcr|
|Gregory J Flesher "Greg"Senior VP:Corporate Dev/Chief Bus Ofcr||Randall E KayeSenior VP:Medical/Chief Medical Ofcr|
|Joao SiffertSenior VP:R&D/Chief Scientific Ofcr||Christine G OcampoVP:Finance/Secretary|